Richard Drury
- Ipsen (IPSEY) to acquire U.S.-based Kartos Therapeutics for $450M in cash, expanding its late-stage oncology portfolio with a Phase III blood cancer therapy.
- Ipsen (IPSEY) said the acquisition aligns with its strategy to build a stronger late-stage oncology franchise
